P0898 Comparative Study on the Efficacy of Biologics with Dietary Intervention in Crohn's Disease: Evaluating the Impact of Crohn's Disease Exclusion Diet and partial Entral nutrition Combination with Biologics

Abstract

Listen

Translate article

Abstract Background Crohn's disease (CD) is a chronic inflammatory condition with significant impact on patient health. While the Crohn's Disease Exclusion Diet (CDED) and partial enteral nutrition (pEN) have shown therapeutic efficacy in CD, real-world study data are limited, and there is a lack of research on the benefits of their combination use with biologic therapies. Methods This retrospective study included CD patients divided into two groups, starting at the initiation of biologics treatment: those receiving biologics alone and those receiving biologics with CDED + pEN for 12 weeks. Clinical outcomes were assessed at baseline, 12, 24, and 48 weeks. Results A total of 51 CD patients were included in the study: 35 received biologics alone, while 16 received biologics with CDED + pEN for 12 weeks. While Crohn’s Disease Activity Index (CDAI) reduction, hemoglobin (Hb) increase, albumin levels, and fecal calprotectin reduction showed no significant differences between groups, notable findings emerged in body weight and C-reactive protein (CRP) levels. The biologics + CDED + pEN group demonstrated a continuous increase in body weight over 48 weeks, whereas the biologics-only group showed a less pronounced trend. Additionally, CRP levels in the CDED + pEN group decreased more rapidly, with significant differences observed by week 12, indicating an early anti-inflammatory effect. Beyond 12 weeks, CRP levels in both groups gradually aligned, but the initial rapid reduction in the combination group highlights the potential of dietary intervention in achieving quicker inflammation control. Despite the discontinuation of CDED + pEN after week 12, the initial benefits in body weight gain and CRP reduction persisted, suggesting lasting effects of the dietary approach when combined with biologics. Conclusion Short-term use of CDED + pEN with biologics may offer early advantages in reducing inflammation and supporting body weight gain in CD treatment.